SPOTLIGHT: Cylene closes $26.3M round

Oncology drug developer Cylene Pharmaceuticals of San Diego has raised $26.3 million in its second round. Coastview Capital led the round, which will fund new research into the company's lead cancer product. Story

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.